Sep 29 2026 12:12 AM EST
Acadia Shares Slip After Mixed Trial Results and Analyst Target Reductions
Acadia Pharmaceuticals (NASDAQ:ACAD) fell more than 20% in the past five trading days, closing near $22 after a Phase 2 Alzheimer’s disease psychosis readout missed its primary endpoint and analysts trimmed price targets despite a 16% year‑over‑year revenue increase in the second quarter.
Q2 2026 GAAP revenue rose to $308 million, driven by NUPLAZID® sales of $183 million and DAYBUE® sales of $125 million. Net income improved to $32 million ($0.18 EPS). Cash and investments increased to $956 million. The company raised full‑year revenue guidance to $1.24‑$1.30 billion, with DAYBUE guidance lifted to $480‑$510 million.
Phase 2 RADIANT Readout Triggers Immediate Sell‑off
The RADIANT trial of remlifanserin (formerly ACP‑204) reported a 12.6‑point improvement versus 10.4 points for placebo on the primary SAPS‑H+D scale, a difference that fell short of statistical significance (p = 0.0603). Management described the data as “highly Phase III enabling” and said the 30 mg arm would be dropped, but the miss prompted a sharp re‑pricing of the pipeline.
Analyst Target Cuts Amplify Downward Pressure
Following the readout, several sell‑side houses trimmed price targets: Needham lowered its target to $35 (from $40), Deutsche Bank to $31 (from $38), BMO Capital to $34 (from $36) and Citizens to $33 (from $36). Consensus fair‑value estimates now sit between $31.80 and $34.68, implying modest upside from the current price.
Insider Sales and Legal Exposure Add to Risk Perception
During the same week, CFO Mark Schneyer sold 14,292 shares at an average price of $29.22, and Principal Accounting Officer James Kihara sold 11,421 shares at $21.18 per share. The company also faces an ongoing securities‑fraud investigation by Glancy Prongay & Murray LLP and a class‑action suit in California alleging misstatements about NUPLAZID® approval prospects. A recent derivative settlement was preliminarily approved on 24 Aug 2026.
Macro‑Economic Headwinds
The broader biotech sector remains sensitive to the Federal Reserve’s “higher‑for‑longer” stance, with 10‑year Treasury yields near 5.2 %. In addition, the Inflation Reduction Act’s Medicare Part D price‑negotiation program, effective 1 Jan 2026, has introduced uncertainty around NUPLAZID® net pricing.
Pipeline Outlook and Strategic Position
Beyond remlifanserin, Acadia expects a positive EMA opinion for DAYBUE® in Rett syndrome and is pursuing a Japan Phase 3 trial with readouts due Sep‑Nov 2026. Management reiterated a 2028 combined net‑sales target of roughly $1.7 billion ($1 billion from NUPLAZID, $0.7 billion from DAYBUE). The cash balance of $956 million provides flexibility for further development or potential acquisitions.
Risks and Uncertainties
Key risks include: (1) further negative or inconclusive data from the remlifanserin program, which could erode the valuation premium built on pipeline potential; (2) ongoing legal proceedings that may result in financial penalties or reputational damage; (3) potential Medicare price‑negotiation impacts on NUPLAZID® margins; and (4) the ability to sustain DAYBUE® growth amid expanding competition and the need for successful European rollout. Investors will watch the upcoming CTAD conference in November for additional efficacy data and any clarification on commercial strategy.